Equities analysts predict that Syros Pharmaceuticals (NASDAQ:SYRS) will announce sales of $1.33 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $370,000.00 to $3.21 million. The company is expected to issue its next earnings report on Wednesday, August 8th.
On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $3.34 million for the current financial year, with estimates ranging from $370,000.00 to $10.00 million. For the next financial year, analysts expect that the business will report sales of $1.53 million per share, with estimates ranging from $600,000.00 to $2.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.14). The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $3.41 million.
Several equities analysts have recently commented on SYRS shares. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. Zacks Investment Research lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price objective (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Cann reaffirmed a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, May 10th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $21.13.
Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in Syros Pharmaceuticals in the fourth quarter worth about $191,000. ARK Investment Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 519.7% during the fourth quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock worth $8,122,000 after purchasing an additional 700,058 shares during the period. Candriam Luxembourg S.C.A. lifted its holdings in shares of Syros Pharmaceuticals by 75.0% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 210,000 shares of the company’s stock worth $2,043,000 after purchasing an additional 90,000 shares during the period. Two Sigma Advisers LP acquired a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth about $105,000. Finally, Adalta Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth about $111,000. 56.84% of the stock is owned by institutional investors and hedge funds.
Shares of Syros Pharmaceuticals stock traded down $0.30 during trading on Friday, hitting $12.78. 2,023 shares of the stock traded hands, compared to its average volume of 245,097. The firm has a market cap of $435.57 million, a P/E ratio of -6.14 and a beta of -2.69. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.